Bégué P, Quinet B, Baron S, Challier P, Fontaine J L, Lasfargues G
Service de Consultation et Maladies Infectieuses de l'Enfant, Hôpital Trousseau, Paris.
Pathol Biol (Paris). 1989 May;37(5):485-90.
Imipenem, a new carbapenem (thienamycin) beta lactam antibiotic which is clinically used in a 1:1 combination with cilastatin, an inhibitor or renal metabolism of imipenem, was evaluated in 25 patients; 11 children and 14 neonates. A mean daily dose of 60 mg/kg was given to children and the dose in neonates was 50 mg/kg. Clinically, 21 patients were cured, two failed to respond to treatment and two were not evaluable. Pharmacokinetic studies were performed in the 11 children and in 10 of the neonates. The mean elimination half-life of imipenem was 0.87 h in children and 2.1 h in neonates. The mean cilastatin elimination half-life was 0.73 h in children and 5.1 h in neonates. This difference in half-life between children and neonates is similar to the one noted between healthy adults and adults with renal insufficiency. No accumulation of imipenem was seen in neonates studied on the first and fifth days of treatment.
亚胺培南是一种新型碳青霉烯类（硫霉素）β-内酰胺抗生素，临床上与亚胺培南肾代谢抑制剂西司他丁按1:1联合使用。对25例患者进行了评估，其中11例为儿童，14例为新生儿。儿童的平均日剂量为60mg/kg，新生儿的剂量为50mg/kg。临床上，21例患者治愈，2例治疗无效，2例无法评估。对11例儿童和10例新生儿进行了药代动力学研究。亚胺培南在儿童中的平均消除半衰期为0.87小时，在新生儿中为2.1小时。西司他丁的平均消除半衰期在儿童中为0.73小时，在新生儿中为5.1小时。儿童和新生儿之间半衰期的这种差异与健康成年人和肾功能不全成年人之间的差异相似。在治疗的第一天和第五天对新生儿进行研究时，未发现亚胺培南有蓄积现象。
